⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RNAZ News
TransCode Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
RNAZ
Form 8-K
sec.gov
RNAZ
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
prnewswire.com
RNAZ
Form 8-K
sec.gov
RNAZ
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
prnewswire.com
RNAZ
Form 8-K/A
sec.gov
RNAZ
Form 8-K
sec.gov
RNAZ
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
prnewswire.com
RNAZ
Form 8-K
sec.gov
RNAZ
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
prnewswire.com
RNAZ